Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: Early results

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Aluwini, Shafak ^a   Van Rooij, Peter ^a   Hoogeman, Mischa ^a   Kirkels, Wim ^a   Kolkman Deurloo, Inger Karine ^a   Bangma, Chris ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical outcome; Low and intermediate risk; Prostate cancer; Radiotherapy; Stereotactic body radiation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYBERKNIFE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; PROSTATE CANCER; PROSTATE VOLUME; QUESTIONNAIRE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; URINARY FREQUENCY; URINE RETENTION; ADVERSE EFFECTS; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOMETRY; RADIOSURGERY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOMETRY; RADIOSURGERY;

EID: 84875887757     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-84     Document Type: Article

References (25)

1. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 2001, 51:213-214.
2. Liao Y, Joiner M, Huang Y, Burmeister J. Hypofractionation: what does it mean for prostate cancer treatment?. Int J Radiat Oncol Biol Phys 2010, 76:260-268. 10.1016/j.ijrobp.2009.06.043, 19879698.
3. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:265-276. 10.1080/02841860410002824, 16076699.
4. Aluwini S, van Rooij PH, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, Kolkman-Deurloo IK. High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naive Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience. Int J Radiat Oncol Biol Phys 2012,
5. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-Dose-Rate Monotherapy: Safe and Effective Brachytherapy for Patients with Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2011, in press.
6. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008, 70:1588-1597. 10.1016/j.ijrobp.2007.11.067, 18374232.
7. Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, Kolkman-Deurloo IK. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 2010, 24:865-869. 10.1089/end.2009.0438, 20433370.
8. Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys 2004, 58:11-18. 10.1016/S0360-3016(03)00820-4, 14697415.
9. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974. 10.1016/j.ijrobp.2006.04.029, 16798415.
10. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006, 107:1496-1502. 10.1002/cncr.22183, 16944536.
11. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012, 61:112-127. 10.1016/j.eururo.2011.09.027, 22001105.
12. Wiegner EA, King CR. Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial. Int J Radiat Oncol Biol Phys 2010, 78:442-448. 10.1016/j.ijrobp.2009.07.1748, 20137864.
13. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006, 64:1140-1150. 10.1016/j.ijrobp.2005.07.006, 16198506.
14. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007, 109:41-47. 10.1002/cncr.22341, 1892752, 17133416.
15. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
16. King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:877-882. 10.1016/j.ijrobp.2010.11.054, 21300474.
17. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
18. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105. 10.1016/j.ijrobp.2006.10.050, 17336216.
19. Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, Lamond J, Brady LW. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol 2011, 34:6-10. 10.1097/COC.0b013e3181c4c7c4, 20065849.
20. Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 2004, 59:242-249. 10.1016/j.ijrobp.2004.01.004, 15093921.
21. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82:228-234. 10.1016/j.ijrobp.2010.10.026, 21183287.
22. HT Pham GS, Badiozamani K, Yao M, Corman J, Hsi RA, Madsen B. Five-year Outcome of Stereotactic Hypofractionated Accurate Radiotherapy of the Prostate (SHARP) for Patients with Low-risk Prostate Cancer. I J Radiation Oncology Biology Physics 2010, 78:s58.
23. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008, 44:2418-2424. 10.1016/j.ejca.2008.07.030, 18774706.
24. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000, 89:1800-1809. 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D, 11042576.
25. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29:2020-2026. 10.1200/JCO.2010.31.4377, 3138546, 21464418.